Postgrad LIVE! Study Fairs

Birmingham | Edinburgh | Liverpool | Sheffield | Southampton | Bristol

CeMM Featured PhD Programmes
Imperial College London Featured PhD Programmes
Birkbeck, University of London Featured PhD Programmes
University of St Andrews Featured PhD Programmes
University College London Featured PhD Programmes
United Kingdom
Leeds×
10 miles

Cancer / Oncology PhD Projects in Leeds

We have 38 Cancer / Oncology PhD Projects in Leeds

  • Cancer / Oncology×
  • United Kingdom×
  • Leeds×
  • PhD Research Project×
  • clear all
Order by 
Showing 1 to 10 of 38
  Understanding drug-resistance in myeloid cancer
  Dr P Laslo
Applications accepted all year round
Under pathogenic challenges, cells of the innate system become epigenetically reprogrammed and establish immune memory.
  Prodrugs Activated by Tumour Microenvironment
  Research Group: Institute of Cancer Therapeutics
  Dr R Wheelhouse, Prof P Loadman, Prof R M Phillips
Applications accepted all year round
The anticancer drug temozolomide (TMZ), has been in the clinic for treating brain tumours for nearly 30 years. Despite its “Blockbuster” status, no other compounds of this class have reached clinical trial.
  Role of hypoxia in promotion of higher grade glioblastoma
  Research Group: Institute of Cancer Therapeutics
  Dr V Vinader, Dr K Afarinkia
Applications accepted all year round
Glioblastomas are categorized into four grades. Grade I is essentially benign and slow growing, and most amenable to treatment. Grade II tumors are larger and invade surrounding tissue.
  Activity based proteomic probes for profiling CYP2W1 in cancer tissues
  Research Group: Institute of Cancer Therapeutics
  Dr C Sutton, Dr K Pors
Applications accepted all year round
Cytochromes P450 (CYPs) are a superfamily of mixed function oxidases of which CYP1-4 subfamily members are unique in their ability to oxidise drugs.
  Exploration of 5-fluorouracil resistance mechanisms in colorectal cancer using 5-FU-resistant xenograft models
  Research Group: Institute of Cancer Therapeutics
  Dr S Shnyder, Dr C Sutton
Applications accepted all year round
Despite therapeutic advances, colorectal cancer (CRC) still has a 45% mortality rate, and one of the major problems is the development of acquired resistance to treatment with anticancer drugs.
  The effect of polysialyltransferase modulation on tumour cell migration
  Research Group: Institute of Cancer Therapeutics
  Dr S Shnyder, Dr R Falconer
Applications accepted all year round
One of the main reasons for failure of cancer therapy today is an inability to control tumour dissemination, with secondary tumour deposits the cause of morbidity.
  The role of tumour microenvironment interactions in melanoma therapy resistance
  Research Group: Institute of Cancer Therapeutics
  Dr H Sheldrake, Dr M Sutherland
Applications accepted all year round
The incidence of malignant melanoma has steadily increased over the past 30 years, and it is predicted that 76,250 new cases will be diagnosed in the US and over 10,000 in the UK this year.
  Synthesis and Characterisation of Proteolysis targeting chimeras (PROTACs), potential anticancer agents
  Research Group: Institute of Cancer Therapeutics
  Dr H Sheldrake
Applications accepted all year round
Proteolysis targeting chimeras (PROTACs) are bifunctional molecules consisting of a small molecule which binds a desired protein target, a linker, and a ligand which binds to an E3 ubiquitin ligase.
  Development of heterocyclic pharmacophores using diversity-oriented synthesis
  Research Group: Institute of Cancer Therapeutics
  Dr K Pors, Prof L Patterson
Applications accepted all year round
Diversity-oriented synthesis (DOS) is a modern chemical tool, which aims to synthesise small molecules that cover new chemical space with the possibility of finding unexplored biological targets or pathways that may be important for disease progression.
  Aldehyde dehydrogenase expression and function in cancer stem cells
  Research Group: Institute of Cancer Therapeutics
  Dr K Pors, Dr A Mardaryev
Applications accepted all year round
Aldehyde dehydrogenases (ALDHs) catalyse the oxidation and detoxification of reactive endogenous and exogenous aldehydes into carboxylic acids via NAD+ coupled reduction (Fig.
Show 10 15 30 per page


FindAPhD. Copyright 2005-2018
All rights reserved.